Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.67 |
| ▸ | HTT | P42858 | 1/20 | 0.67 |
| ▸ | MEN1 | O00255 | 3/20 | 0.61 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.61 |
| ▸ | POLB | P06746 | 1/20 | 0.59 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.59 |
| ▸ | AR | P10275 | 9/20 | 0.56 |
| ▸ | BACE1 | P56817 | 1/20 | 0.53 |
| ▸ | LMNA | P02545 | 1/20 | 0.47 |
| ▸ | MCOLN3 | Q8TDD5 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6106505 | 0.89 | KDM4E (0.54) | KDM4EHTTMEN1KMT2APOLB | |
| SCHEMBL5865930 | 0.87 | AR (0.58) | KDM4EHTTAR | |
| SCHEMBL5865922 | 0.87 | AR (0.62) | KDM4EHTTAR | |
| SCHEMBL5865857 | 0.86 | AR (0.60) | KDM4EHTTARBACE1 | |
| SCHEMBL5865849 | 0.86 | AR (0.60) | KDM4EHTTARBACE1 | |
| SCHEMBL5865880 | 0.86 | AR (0.60) | KDM4EHTTARBACE1 | |
| SCHEMBL5865853 | 0.86 | AR (0.53) | KDM4EHTTMEN1KMT2AHSD17B10 | |
| SCHEMBL5865940 | 0.84 | ALDH1A1 (0.61) | KDM4EHTTMEN1KMT2AHSD17B10 | |
| SCHEMBL5865902 | 0.83 | SMN1; SMN2 (0.60) | KDM4EHTTAR | |
| SCHEMBL5865908 | 0.82 | KDM4E (0.66) | KDM4EHTTMEN1KMT2APOLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7064207-B2 | 6-sulfonamido-quinolin-2-one and 6-sulfonamido-2-oxo-chromene derivatives, useful for treating alopecia, acne and oily skin | WARNER LAMBERT COMPANY LLC (US) | 2006-06-20 | — | — | US | claimed |
| US-20050085467-A1 | Androgen receptor antagonists | DU DANIEL Y (US) | 2005-04-21 | — | — | US | claimed |
| US-7064207-B2 | 6-sulfonamido-quinolin-2-one and 6-sulfonamido-2-oxo-chromene derivatives, useful for treating alopecia, acne and oily skin | WARNER LAMBERT COMPANY LLC (US) | 2006-06-20 | — | — | US | disclosed |
| EP-1587804-A1 | ANDROGEN RECEPTOR ANTAGONISTS | Warner-Lambert Company LLC (US) | 2005-10-26 | — | — | EP | disclosed |
| US-20050085467-A1 | Androgen receptor antagonists | DU DANIEL Y (US) | 2005-04-21 | — | — | US | disclosed |
| WO-2004065379-A1 | ANDROGEN RECEPTOR ANTAGONISTS | WARNER-LAMBERT COMPANY LLC (US) | 2004-08-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050085467-A1 | Androgen receptor antagonists | AR, NR5A1, ESRRB | KDM4E 2570/4885HTT 4253/4885MEN1 3029/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.